Teva Pharma (TEVA) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY25 Revenue Guidance

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.66, $0.03 better than the analyst estimate of $0.63. Revenue for the quarter came in at $4.2 billion versus the consensus estimate of $4.28 billion.

GUIDANCE:

Teva Pharma sees FY2025 revenue of $16.8-17.2 billion, versus the consensus of $16.92 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• Hertz cuts guidance, announces notes and stock offerings, shares sink
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Trump: Iran Informed There Are No Tolls In Hormuz